{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T16:32:05Z","timestamp":1762446725636,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone Reports"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.bonr.2022.101178","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T05:42:02Z","timestamp":1646372522000},"page":"101178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Bisphosphonates and bone mineral density in patients with end-stage kidney disease and renal transplants: A 15-year single-centre experience"],"prefix":"10.1016","volume":"16","author":[{"given":"Dominic","family":"Hauck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liza","family":"Nery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"O'Connell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roderick","family":"Clifton-Bligh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Mather","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian M.","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bonr.2022.101178_bb0005","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1046\/j.1523-1755.2000.00178.x","article-title":"Increased risk of hip fracture among patients with end-stage renal disease","volume":"58","author":"Alem","year":"2000","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.bonr.2022.101178_bb0010","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11914-017-0361-4","article-title":"What animal models have taught us about the safety and efficacy of bisphosphonates in chronic kidney disease","volume":"15","author":"Allen","year":"2017","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.bonr.2022.101178_bb0015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000276666","article-title":"Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series","volume":"29","author":"Amerling","year":"2010","journal-title":"Blood Purif."},{"issue":"5","key":"10.1016\/j.bonr.2022.101178_bb0020","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/jbmr.5650010503","article-title":"Aluminum-associated bone disease in chronic renal failure: high prevalence in a long-term dialysis population","volume":"1","author":"Andress","year":"1986","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bonr.2022.101178_bb0025","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40620-017-0404-z","article-title":"Osteoporosis, bone mineral density and CKD-MBD: treatment considerations","volume":"30","author":"Bover","year":"2017","journal-title":"J. Nephrol."},{"issue":"3","key":"10.1016\/j.bonr.2022.101178_bb0030","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/jbmr.2074","article-title":"Bone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women: randomized comparison to alendronate","volume":"29","author":"Chavassieux","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.bonr.2022.101178_bb0035","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1097\/01.ASN.0000087092.53894.80","article-title":"Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate","volume":"14","author":"Coco","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"year":"2017","series-title":"Chronic Kidney Disease Compendium","author":"<collab>Welfare","key":"10.1016\/j.bonr.2022.101178_bb0040"},{"issue":"3","key":"10.1016\/j.bonr.2022.101178_bb0045","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MNH.0000000000000411","article-title":"Fracture risk and treatment in chronic kidney disease","volume":"27","author":"Connelly","year":"2018","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"1","key":"10.1016\/j.bonr.2022.101178_bb0050","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.ajkd.2005.09.024","article-title":"PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis","volume":"47","author":"Danese","year":"2006","journal-title":"Am. J. Kidney Dis."},{"issue":"4","key":"10.1016\/j.bonr.2022.101178_bb0055","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1359\/jbmr.070112","article-title":"Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial","volume":"22","author":"Jamal","year":"2007","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bonr.2022.101178_bb0060","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00198-019-05187-0","article-title":"The prevalence and incidence of vertebral fractures in end-stage renal disease and the role of parathyroid hormone","volume":"31","author":"Jansz","year":"2020","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.bonr.2022.101178_bb0065","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/jbmr.1756","article-title":"Direct medical resource utilization associated with osteoporosis-related nonvertebral fractures in postmenopausal women","volume":"28","author":"Jean","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bonr.2022.101178_bb0070","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what's changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.bonr.2022.101178_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/837573","article-title":"Bisphosphonates in CKD patients with low bone mineral density","volume":"2013","author":"Liu","year":"2013","journal-title":"Sci. World J."},{"issue":"5","key":"10.1016\/j.bonr.2022.101178_bb0080","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00198-019-05267-1","article-title":"Comparison of the clinical effectiveness and safety between the use of denosumab vs bisphosphonates in renal transplant patients","volume":"31","author":"McKee","year":"2020","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bonr.2022.101178_bb0085","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/bonekey.2014.37","article-title":"Chronic kidney disease and osteoporosis: evaluation and management","volume":"3","author":"Miller","year":"2014","journal-title":"Bonekey Rep."},{"issue":"2","key":"10.1016\/j.bonr.2022.101178_bb0090","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1053\/j.ajkd.2013.12.018","article-title":"Bone disease in CKD: a focus on osteoporosis diagnosis and management","volume":"64","author":"Miller","year":"2014","journal-title":"Am. J. Kidney Dis."},{"issue":"4","key":"10.1016\/j.bonr.2022.101178_bb0095","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/jbmr.2089","article-title":"A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD","volume":"29","author":"Moe","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"24","key":"10.1016\/j.bonr.2022.101178_bb0100","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.2169\/internalmedicine.8618-16","article-title":"Management of osteoporosis in chronic kidney disease","volume":"56","author":"Nitta","year":"2017","journal-title":"Intern. Med."},{"issue":"11","key":"10.1016\/j.bonr.2022.101178_bb0105","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nrneph.2013.182","article-title":"Therapy for patients with CKD and low bone mineral density","volume":"9","author":"Ott","year":"2013","journal-title":"Nat. Rev. Nephrol."},{"issue":"4","key":"10.1016\/j.bonr.2022.101178_bb0110","doi-asserted-by":"crossref","first-page":"JC19","DOI":"10.7326\/ACPJC-2017-167-4-019","article-title":"Review: osteoporosis drugs may improve BMD and reduce fractures in some patients with CKD","volume":"167","author":"Ott","year":"2017","journal-title":"Ann. Intern. Med."},{"issue":"5","key":"10.1016\/j.bonr.2022.101178_bb0115","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.ajkd.2019.10.019","article-title":"Interventions for preventing bone disease in kidney transplant recipients: editorial summary of a Cochrane review","volume":"75","author":"Palmer","year":"2020","journal-title":"Am. J. Kidney Dis."},{"issue":"5","key":"10.1016\/j.bonr.2022.101178_bb0120","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/jbmr.4235","article-title":"Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a binational cohort analysis","volume":"36","author":"Robinson","year":"2021","journal-title":"J. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.bonr.2022.101178_bb0125","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s10067-015-2883-4","article-title":"Treatment of osteoporosis in renal insufficiency","volume":"34","author":"Schipper","year":"2015","journal-title":"Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.bonr.2022.101178_bb0130","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2215\/CJN.02550508","article-title":"Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue","volume":"4","author":"Toussaint","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.bonr.2022.101178_bb0135","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1053\/j.ajkd.2008.11.036","article-title":"Effect of pamidronate on bone loss after kidney transplantation: a randomized trial","volume":"53","author":"Walsh","year":"2009","journal-title":"Am. J. Kidney Dis."},{"issue":"5","key":"10.1016\/j.bonr.2022.101178_bb0140","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s00198-015-3465-7","article-title":"Bisphosphonates for prevention of osteopenia in kidney-transplant recipients: a systematic review of randomized controlled trials","volume":"27","author":"Wang","year":"2016","journal-title":"Osteoporos. Int."},{"issue":"9","key":"10.1016\/j.bonr.2022.101178_bb0145","doi-asserted-by":"crossref","first-page":"649","DOI":"10.7326\/M16-2752","article-title":"Benefits and harms of osteoporosis medications in patients with chronic kidney disease: a systematic review and meta-analysiseffect of osteoporosis medications in patients with CKD","volume":"166","author":"Wilson","year":"2017","journal-title":"Ann. Intern. Med."}],"container-title":["Bone Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187222000134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187222000134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T16:25:20Z","timestamp":1762446320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352187222000134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":29,"alternative-id":["S2352187222000134"],"URL":"https:\/\/doi.org\/10.1016\/j.bonr.2022.101178","relation":{},"ISSN":["2352-1872"],"issn-type":[{"type":"print","value":"2352-1872"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bisphosphonates and bone mineral density in patients with end-stage kidney disease and renal transplants: A 15-year single-centre experience","name":"articletitle","label":"Article Title"},{"value":"Bone Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bonr.2022.101178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101178"}}